BMS-986517 / BMS - LARVOL DELTA

A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=315 | Recruiting | Sponsor: Bristol-Myers Squibb | Not yet recruiting ➔ Recruiting

Enrollment open • First-in-human • Monotherapy • Solid Tumor

A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=315 | Not yet recruiting | Sponsor: Bristol-Myers Squibb

Monotherapy • New P1/2 trial • Solid Tumor